Press

Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehensive clinical study program

 

3 sep, 2018

Acarix AB (publ) (“Acarix”), today reported positive feedback for the clinical study program in order to validate and expand the performance of the CADScor®System.

Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehen

 

About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.